Mydecine Innovations Group Aktie

Vancouver, British Columbia – TheNewswire - May 15, 2025 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is providing this update on the status of a management cease trade order granted on May 1, 2025 (the " MCTO ") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order (" NP 12-203 "). On May 1, 2025, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2024 (the " Annual Filings ") beyond the period prescribed under applicable Canadian securities laws (the " Default Announcement "). The Company reports that the audit is progressing and will provide a further update on the timing of its Annual Filings on or about May 29, 2025. The Company is also progressing on completion of its interim financial statements and accompanying management's discussion and analysis for the first quarter ended March 31, 2025, and will provide a further update on or about May 29, 2025. Further updates on timing will be provided by the Company as necessary.» Mehr auf thenewswire.com

Vancouver, British Columbia, May 01, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) announces today that as a result of delays to its audit, the Company's annual financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2024 (the “Annual Filings”), the Company has determined that they may not be able to file the Required Filings by the Filing Deadline as required by Part 4 of National Instrument 51-102 Continuous Disclosure Obligations. The reason for the anticipated delay is primarily due to the late commencement of the audit process, which was caused by the Company's financial constraints. These constraints resulted in outstanding fees owed to the external auditor for the prior year's audit. As a result, the Company was unable to engage its auditor to commence the audit for the current year. In addition, a recent change in management further impacted the timing of the audit process, as the management team works to obtain certain outstanding records essential to the audit. The Company has since secured the necessary funding to satisfy the outstanding obligations and has now re-engaged its auditor to proceed with the audit. The Company is working with its auditor ( HDCPA Professional Corporation ) to complete the audit in a timely manner. The Company currently expects to file the Annual Filings on or before June 30, 2025 and will issue a news release announcing completion of such filings at such time. Until the Company files the Annual Filings, it will comply with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Order for issuers who have failed to comply with a specified continuous disclosure requirement within the times prescribed by applicable securities laws. The guidelines, among other things, require the Company to issue bi-weekly default status reports by way of a news release so long as the Annual Filings have not been filed.» Mehr auf thenewswire.com

Vancouver, British Columbia, March 26, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce the appointments of Mr. Peter Field to its board of directors, effective March 18, 2025. Mr. Field is a seasoned entrepreneur with over 30 years of experience in business development, product innovation, and leadership. Based in Vancouver, he has been involved in ventures leveraging advanced technologies, including an AI-driven vertical farming platform and pharmaceutical commercialization. He has helped build and manage two GMP, USFDA-certified manufacturing facilities and has invested in biotech companies focused on wound care, Alzheimer's, depression, and cancer biomarkers. More recently, as President of a biotech company, Mr. Field has as gained extensive experience in public markets, capital raises, and regulatory compliance, playing a pivotal role in securing funding and guiding corporate governance.» Mehr auf thenewswire.com